Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
54.7M
-
Number of holders
-
118
-
Total 13F shares, excl. options
-
53.8M
-
Shares change
-
+197K
-
Total reported value, excl. options
-
$486M
-
Value change
-
+$383K
-
Put/Call ratio
-
1.56
-
Number of buys
-
58
-
Number of sells
-
-46
-
Price
-
$9.04
Significant Holders of Marinus Pharmaceuticals, Inc. - Common Stock (MRNS) as of Q1 2024
153 filings reported holding MRNS - Marinus Pharmaceuticals, Inc. - Common Stock as of Q1 2024.
Marinus Pharmaceuticals, Inc. - Common Stock (MRNS) has 118 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 53.8M shares
of 54.7M outstanding shares and own 98.32% of the company stock.
Largest 10 shareholders include SUVRETTA CAPITAL MANAGEMENT, LLC (5.11M shares), BlackRock Inc. (4.72M shares), Avoro Capital Advisors LLC (4.14M shares), FRANKLIN RESOURCES INC (3.49M shares), Cormorant Asset Management, LP (3.25M shares), JENNISON ASSOCIATES LLC (2.97M shares), VANGUARD GROUP INC (2.81M shares), EVENTIDE ASSET MANAGEMENT, LLC (2.35M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.33M shares), and Lion Point Capital, LP (2.12M shares).
This table shows the top 118 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.